Allogene Therapeutics, Inc. (NASDAQ:ALLO) was founded in 2017, headquartered in South San Francisco, California, USA, with 78 full-time employees (9/30/2018). It is a clinical stage immuno-oncology company focusing on genetic engineering and The development and commercialization of a kind of allogeneic T cell therapy for the treatment of cancer.
Allogene Therapeutics (ALLO):
Allogene Therapeutics is a clinical stage biotechnology company that pioneered the development of allogeneic chimeric antigen receptor T cell (CAR T) therapy for cancer. Under the leadership of a world-class management team with rich experience in cell therapy, the company is developing an “off-the-shelf” CAR T cell therapy candidate drug, and its goal is to provide more patients with faster, more reliable and larger scale Cell therapy.
Allogene Therapeutics is developing a line of ready-made T cell candidates designed to target and kill cancer cells. The company’s engineered T cells are allogeneic, which means that they come from healthy donors and are used in any patient, rather than individual patients from the patient, as in the case of autologous T cells. Allogene Therapeutics believes that this key difference will enable us to provide ready-made treatment options to more patients faster, more reliably, and on a larger scale.
Allogene Therapeutics (ALLO) investment:
Allogene Therapeutics, Inc. (NASDAQ:ALLO) submitted its IPO prospectus on 9/14/2018, and landed on Nasdaq on 10/11/2018. The issue price was US$18.00, 16 million shares were issued, and US$288 million was raised. Underwriting by Goldman Sachs/ JP Morgan/ Cowen/ Jefferies.
